{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:56:26Z","timestamp":1791878186128,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005612","name":"Shionogi and Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jgar.2026.08.011","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:46:06Z","timestamp":1786981566000},"page":"462-469","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["In vitro activity of cefiderocol against highly resistant Gram-negative pathogens collected in the SENTRY Surveillance Program between 2020 and 2024"],"prefix":"10.1016","volume":"50","author":[{"given":"Boudewijn L.M.","family":"DeJonge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5586-7256","authenticated-orcid":false,"given":"Christopher","family":"Longshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Kung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4779-2100","authenticated-orcid":false,"given":"Sean T.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8648-1137","authenticated-orcid":false,"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7860-8863","authenticated-orcid":false,"given":"Yoshinori","family":"Yamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2026.08.011_bib0001","unstructured":"World Health Organization. WHO bacterial priority pathogens list, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. [accessed 31.03.26] https:\/\/www.who.int\/publications\/i\/item\/9789240093461."},{"key":"10.1016\/j.jgar.2026.08.011_bib0002","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/S0140-6736(22)02185-7","article-title":"Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2026.08.011_bib0003","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","article-title":"Global burden of bacterial antimicrobial resistance 1990\u20132021: a systematic analysis with forecasts to 2050","volume":"404","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2026.08.011_bib0004","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/13543784.2024.2326028","article-title":"Antibacterial agents active against gram negative bacilli in phase I, II, or III clinical trials","volume":"33","author":"Paterson","year":"2024","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jgar.2026.08.011_bib0005","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02712-21","article-title":"In vitro activity of cefiderocol against U.S. and European gram-negative clinical isolates collected in 2020 as part of the SENTRY Antimicrobial Surveillance Program","volume":"10","author":"Shortridge","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jgar.2026.08.011_bib0006","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2023.28.39.2200805","article-title":"Healthcare-associated infections by multidrug-resistant bacteria in Andalusia, Spain, 2014 to 2021","volume":"28","author":"Fern\u00e1ndez-Mart\u00ednez","year":"2023","journal-title":"Euro Surveill"},{"key":"10.1016\/j.jgar.2026.08.011_bib0007","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2023.28.42.2300522","article-title":"Rapid spread of a novel NDM-producing clone of Klebsiella pneumoniae CC147, Northern Italy, February to August 2023","volume":"28","author":"Mileto","year":"2023","journal-title":"Euro Surveill"},{"key":"10.1016\/j.jgar.2026.08.011_bib0008","doi-asserted-by":"crossref","first-page":"ofad609","DOI":"10.1093\/ofid\/ofad609","article-title":"Trends in incidence of carbapenem-resistant enterobacterales in 7 US sites, 2016\u20132020","volume":"10","author":"Duffy","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"Suppl 7","key":"10.1016\/j.jgar.2026.08.011_bib0009","doi-asserted-by":"crossref","first-page":"S538","DOI":"10.1093\/cid\/ciz826","article-title":"Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin","volume":"69","author":"Sato","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2026.08.011_bib0010","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00346-23","article-title":"In vitro and in vivo activity of cefiderocol against Achromobacter spp. And Burkholderia cepacia complex, including carbapenem-non-susceptible isolates","volume":"67","author":"Takemura","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.08.011_bib0011","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1093\/jac\/dkad200","article-title":"In vitro activity of cefiderocol against MBL-producing gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014\u20132019)","volume":"78","author":"Takemura","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2026.08.011_bib0012","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1089\/mdr.2022.0279","article-title":"In vitro activity of cefiderocol against meropenem-nonsusceptible gram-negative bacilli with defined \u03b2-lactamase carriage: SIDERO-WT Surveillance Studies, 2014\u20132019","volume":"29","author":"Wise","year":"2023","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.jgar.2026.08.011_bib0013","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01474-24","volume":"12","author":"Kimbrough","year":"2024","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jgar.2026.08.011_bib0014","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard \u2013 eleventh edition","year":"2024"},{"key":"10.1016\/j.jgar.2026.08.011_bib0015","series-title":"Performance standards for antimicrobial susceptibility testing; 36th informational supplement, M100-S36","year":"2026"},{"key":"10.1016\/j.jgar.2026.08.011_bib0016","series-title":"Clinical breakpoints","year":"2026"},{"key":"10.1016\/j.jgar.2026.08.011_bib0017","series-title":"Antibacterial susceptibility test interpretive criteria","year":"2026"},{"key":"10.1016\/j.jgar.2026.08.011_bib0018","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 Guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2026.08.011_bib0019","article-title":"In vitro activity of cefiderocol against European Enterobacterales, including isolates resistant to meropenem and recent \u03b2-lactam\/\u03b2-lactamase inhibitor combinations","volume":"12","author":"Santerre Henriksen","year":"2024","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jgar.2026.08.011_bib0020","article-title":"In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent \u03b2-lactam\/\u03b2-lactamase inhibitor combinations","volume":"12","author":"Santerre Henriksen","year":"2024","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jgar.2026.08.011_bib0021","doi-asserted-by":"crossref","unstructured":"Karlowsky JA, Hackel MA, Takemura M, Yamano Y, Echols R, Sahm DF. In vitro susceptibility of gram-negative pathogens to cefiderocol in five consecutive annual multinational SIDERO-WT surveillance studies, 2014 to 2019. Antimicrob Agents Chemother 2022;66:e0199021. https:\/\/doi.org\/10.1128\/AAC.01990-21. Erratum in: Antimicrob Agents Chemother 2023;67:e0042723.","DOI":"10.1128\/aac.00427-23"},{"issue":"2","key":"10.1016\/j.jgar.2026.08.011_bib0022","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.cmi.2023.08.029","article-title":"Global prevalence of cefiderocol non-susceptibility in enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis","volume":"30","author":"Karakonstantis","year":"2024","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"10.1016\/j.jgar.2026.08.011_bib0023","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02163-17","article-title":"Pharmacokinetics, safety, and tolerability of cefiderocol, a novel siderophore cephalosporin for gram-negative bacteria, in healthy subjects","volume":"62","author":"Saisho","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.jgar.2026.08.011_bib0024","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1093\/jac\/dkab280","article-title":"Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia","volume":"76","author":"Katsube","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.jgar.2026.08.011_bib0025","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/jbcr\/irae026","article-title":"Bone and skin\/subcutaneous tissue concentrations of cefiderocol during treatment of extensively drug-resistant Pseudomonas aeruginosa","volume":"45","author":"Mueller","year":"2024","journal-title":"J Burn Care Res"},{"issue":"12","key":"10.1016\/j.jgar.2026.08.011_bib0026","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1093\/jac\/dkae359","article-title":"Target-site cefiderocol pharmacokinetics in soft tissues of healthy volunteers","volume":"79","author":"Sanz-Codina","year":"2024","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.jgar.2026.08.011_bib0027","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/phar.4632","article-title":"Pharmacokinetics of cefiderocol in a patient with carbapenem-resistant Acinetobacter baumannii ventriculitis: a case report","volume":"45","author":"Finch","year":"2025","journal-title":"Pharmacotherapy"},{"issue":"Suppl 2","key":"10.1016\/j.jgar.2026.08.011_bib0028","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1093\/cid\/ciad095","article-title":"Durlobactam, a broad-spectrum serine \u03b2-lactamase inhibitor, restores sulbactam activity against Acinetobacter species","volume":"76","author":"Papp-Wallace","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2026.08.011_bib0029","article-title":"Case report: successful treatment of OXA-23 Acinetobacter baumannii neurosurgical infection and meningitis with sulbactam-durlobactam combination therapy","volume":"11","author":"Snowdin","year":"2024","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"10.1016\/j.jgar.2026.08.011_bib0030","doi-asserted-by":"crossref","DOI":"10.1128\/asmcr.00069-24","article-title":"Management of extensively drug-resistant Acinetobacter baumannii bacteremia with cefiderocol and sulbactam-durlobactam: a case report","volume":"1","author":"Kim","year":"2025","journal-title":"ASM Case Rep"},{"issue":"10","key":"10.1016\/j.jgar.2026.08.011_bib0031","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf618","article-title":"Turning the tide against carbapenem-resistant Acinetobacter baumannii: advancing care with sulbactam-durlobactam","volume":"12","author":"Satlin","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2026.08.011_bib0032","doi-asserted-by":"crossref","unstructured":"Zhan Y, Mao W, Zhao C, Lu D, Chen C, Hu W, et al. Comparison of cefiderocol and colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review with meta-analysis and trial sequential analysis. BMC Infect Dis 2024;24(1):967. https:\/\/doi.org\/10.1186\/s12879-024-09899-5. Erratum in: BMC Infect Dis 2024;24(1):1086. 10.1186\/s12879-024-09979-6.","DOI":"10.1186\/s12879-024-09979-6"},{"issue":"3","key":"10.1016\/j.jgar.2026.08.011_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2026.107718","article-title":"Resistance to sulbactam\/durlobactam in carbapenem-resistant Acinetobacter baumannii in treatment-naive setting: in vitro data and genomic insights from Italian bloodstream isolates","volume":"67","author":"Bianco","year":"2026","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"10.1016\/j.jgar.2026.08.011_bib0034","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s10096-025-05109-5","article-title":"Cefiderocol treatment for patients infected by Stenotrophomonas maltophilia, Burkholderia cepacia complex and Achromobacter spp.: subgroup analysis from the PERSEUS study","volume":"44","author":"Torre-Cisneros","year":"2025","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2026.08.011_bib0035","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1055\/s-0035-1546752","article-title":"The microbiome and emerging pathogens in cystic fibrosis and non-cystic fibrosis bronchiectasis","volume":"36","author":"Green","year":"2015","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.jgar.2026.08.011_bib0036","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01025-20","article-title":"Achromobacter infections and treatment options","volume":"64","author":"Isler","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.08.011_bib0037","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jgar.2024.01.023","article-title":"In vitro activity of cefiderocol against gram-negative pathogens isolated from people with cystic fibrosis and bronchiectasis","volume":"36","author":"Tunney","year":"2024","journal-title":"J Glob Antimicrob Resist"},{"issue":"2","key":"10.1016\/j.jgar.2026.08.011_bib0038","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.01480-24","article-title":"Evaluation of antimicrobial susceptibility testing methods for Burkholderia cepacia complex isolates from people with and without cystic fibrosis","volume":"63","author":"Jorth","year":"2025","journal-title":"J Clin Microbiol"},{"issue":"9","key":"10.1016\/j.jgar.2026.08.011_bib0039","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.00471-25","article-title":"The impact of commercially available media on cefiderocol susceptibility testing by broth microdilution method","volume":"63","author":"DeJonge","year":"2025","journal-title":"J Clin Microbiol."}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716526001451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716526001451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:53:03Z","timestamp":1790178783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716526001451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":39,"alternative-id":["S2213716526001451"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2026.08.011","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of cefiderocol against highly resistant Gram-negative pathogens collected in the SENTRY Surveillance Program between 2020 and 2024","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2026.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Shionogi. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}